Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis  by Jones, Adrian C. et al.
Osteoarthritis and Cartilage (1995) 3, 269-273 
© 1995 Osteoarthritis Research Society 1063-4584/95/040269 + 05 $12.00/0 
OSTEOARTHRITIS 
and 
CARTILAGE 
Intra-art icular hyaluronic acid compared to intra-art icular 
t r iamcino lone hexaceton ide in in f lammatory  knee osteoarthr i t is  
BY ADRIAN C. JONES, MARTIN PATTRICK*, SALLY DOHERTY AND MICHAEL DOHERTY 
Rheumatology Unit, City Hospital, Hucknall Road, Nottingham NG51PB, U..K. 
Summary  
The aim of this study was to determine the comparative fficacy and safety of intra-artieular (i/a) triamcinolone 
hexacetonide (TH) and i/a hyaluronic acid (HA) in inflammatory knee osteoarthritis. A randomized ouble-blind 
comparative trial was carried out in a rheumatology outpatient department. There were 63 patients (24 male, 39 female, 
mean age 70.5 years) with bilateral symptomatic knee osteoarthritis with effusion. Each was given five HA injections at 
weekly intervals; or 20 mg TH followed by four placebo (saline) injections. Patients were examined weekly during the 
treatment period and then at monthly intervals for a further 6 months. Assessment included recording of: visual analog 
scores (VAS) for pain; duration of stiffness; range of movement; joint effusion; local heat; synovial thickening; joint-line 
and periarticular tenderness. The principal outcome measure was pain on a self-selected activity assessed by VAS. The 
two groups were comparable at entry and no significant differences between the groups developed at any time during 
the treatment period. However there was a high drop-out rate and intention to treat analysis failed to demonstrate 
statistically significant differences between the groups. In patients remaining in the study, significantly less pain was 
experienced by the HA group during the 6 month follow-up period. Other parameters showed a similar trend in favor of 
HA. We could not, however, demonstrate significant differences between the placebo and active treatments. HA may 
therefore be a useful additional therapy for symptomatic knee osteoarthritis and may have a long duration of action. 
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I n t roduct ion  
CURRENT therapeut ic  strategies in os teoar thr i t i s  
are l imited [1]. A l though in t ra -ar t i cu lar  cort icos- 
teroids are widely employed, the i r  use is controver-  
sial [2] and object ive evidence of benefit  l imited 
[3-5]. Hya luron ic  acid (HA) has been suggested to 
be of symptomat ic  benef it  in osteoar thr i t i s  and in 
addit ion may have a long durat ion of act ion [6-8]. 
This s tudyd i rec t ly  compares  HA against  tri- 
amcino lone hexaceton ide  (TH) in the t reatment  of 
pat ients  with ' in f lammatory '  knee osteoarthr i t is .  
Pat ients  with b i latera l  effusions were selected so 
that  the eff icacy of both therapies  could also be 
compared  to p lacebo in ject ion in the cont ra la tera l  
knee. 
Methods  
Sixty-three pat ients  referred to a single hosp i ta l  
with b i latera l  knee osteoar thr i t i s  with b i latera l  
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effusions were studied. All pat ients  were assessed 
to exclude coexistent  rheumato log ica l  or ser ious 
medica l  disease. This assessment  included: past  
medica l  and rheumato log ica l  history; ful l  medica l  
and rheumato log ica l  cl inical examinat ion;  and 
detai ls of medicat ion  dur ing the last year. Radio- 
graphs of the knees (weight-bear ing anteroposter io r  
and lateral  view in 30 ° flexion) were read for 
indiv idual  features of osteoarthr i t i s  [9, 10]. Pat ients  
tak ing  non-steroidal  ant i - in f lammatory  drugs 
(NSAIDs) were asked to d iscont inue them for the 
durat ion of the study and to use paracetamol  for 
ana lges ia  instead. 
Each knee was assessed at each visit  us ing 10 cm 
visual  ana log scales (VAS) for pain on a self-selected 
activity, at rest  and at night.  Pat ient 's  self-selected 
act iv i ty was the phys ica l  act iv ity which they felt 
most  aggravated the i r  knee pain. Throughout  the 
init ia l  t reatment  per iod a daily VAS for self-selected 
knee pain  and paracetamol  use was also recorded in 
a pat ient  diary. Pat ients  were included in the study 
if, dur ing the 2-week run- in period, the d iary 
recorded an average of >30 mm for self-selected 
knee pain  in both  knees. Ev idence of cl inical 
in f lammat ion was gaged using a prev ious ly  de- 
scr ibed score for knee in f lammat ion [11, 12]. In br ie f  
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Table I 
Patient characteristics at entry to the study 
Hyaluronic acid Triamcinolone 
group group 
32 31 
21:10 
+_ 1.4 69.5 ± 1.7 
Number of subjects 
Gender (male:female) 
Age (mean ± S.D.) 
Symptoms: 
Swelling 
Locking 
Giving way 
Total X-ray score (mean ± S.D.) 
Visual analog scores for pain: 
On nominated activity 
At rest 
At night 
Volume of fluid aspirated (ml) 
(median, interquartile range) 
18:14 
71.4 
31 (97%) 29 (94%) 
17 (53%) 24 (77%) 
23 (72%) 27  (87%) 
9.5 _+3.3 9.8 _+3.3 
77.2 ±3.3 75.8 ±3.0 
53.2 ±5.6 55.3 ±5.3 
62.2 ±6.2 62.2 ±5.3 
10 5,25.5 10 2,20 
this comprises assessment of early morning and 
inactivity stiffness, local tenderness, local heat, 
effusion and synovial thickening. 
Active treatment was by weekly injection of either 
five doses of 20 mg HA (Hyalgan, Fidia SPA) (HA 
group) or 20 mg TH followed by four placebo doses 
(TH group). Although patients were randomized as 
to the active treatment received, this was always 
given to the worst knee. The contralateral knee 
received five placebo injections. The placebo 
comprised I ml of 0.9% saline. Since the viscosity 
of HA makes 'blinding' of the injector impossible, 
all assessments were made by a separate 'blind' 
investigator. All injections were performed after 
first attempting to aspirate the joint to dryness. 
The study was approved by the local Medical 
Ethics Committee and written informed consent 
was obtained. The number of patients was calcu- 
lated so as to detect a 20 mm difference between the 
treatments with a power of 80% and a between 
patient expected standard eviation of 24 mm [13]; 
the principal outcome measure being pain on 
nominated activity assessed by VAS. No allowance 
was made for possible drop-outs. Total X-ray score 
was obtained by summating the individual scores for 
osteophyte and joint space narrowing for all three 
compartments of the knee. Analysis of the results 
was performed using the SAS statistical package 
and two-tailed tests with a significance level of 5% 
were used throughout. 
Resu l ts  
Sixty-three patients were recruited into the study 
and both treatment groups were comparable in all 
respects (Table I). During the 2-week run-in period 
there was an overall deterioration in symptoms 
presumably consequent upon withdrawal of NSAID 
medication. No significant difference in any 
parameter between the TH- and HA-treated knees 
was observed uring the initial 5-week treatment 
period; all groups showed a tendency to improve- 
ment over the baseline measurement. Seven patients 
withdrew during this period (Table II). 
Table II 
Patient withdrawals during the study 
Hyaluronic acid Triamcinolone 
group group 
Total 19 (3) 23 (4) 
Worsening of knee symptoms 10 (2) 9 
Slow improvement 2 4 
Concomitant medication for osteoarthritis 1 3 (2) 
Concomitant medication for other disease 2 2 (1) 
Urticara + mouth and genital ulcers 0 1 
Intercurrent illness 4 (1) 4 (1) 
Numbers in parentheses are the number of patients who were withdrawn during the initial active ,
treatment period. 
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Table II I  
Summary statistics for the major outcome measures during the trial 
Week 0 Week 4 Week 29 
HA TA HA TA HA TA 
N= 32 N= 31 N= 29 N= 27 N= 12 N= 8 
Active knees 
Pain 
Nominated 77.2 _+ 3.3 75.8 ± 3.0 56.5 ± 6.3 56.7 _+ 6.1 44.3 ± 7.2 54.3 ± 8.5 
Activity 
Rest 53.2 ± 5.6 55.3 ± 5.3 39.9 _+ 6.4 40.6 _+ 6.2 28.2 ± 7.2 48.6 _+ 9.6 
Night 57.8 ± 6.2 62.2 ± 5.3 35.9 ± 5.9 43.0 _+ 6.5 15.4 ± 4.4 36.1 _+ 7.5 
Volume aspirated (median, 10 10 10 15 5 15 
interquartile range) 5, 25.5 2, 20 i, 16 3.5, 29.5 5.5, 11.5 12, 48 
Placebo knees 
Pa in  
Nominated 68.6 ± 3.9 66.2 ___ 4.5 47~0 ± 6.5 51.7 _+ 5.9 38.3 _ 7.5 53.4 _+ 7.6 
Activity 
Rest 43.1 + 5.4 41.3 ± 5.2 27.9 _+ 5.4 34.9 _ 5.4 17.9 + 7.1 30.5 _+ 7.5 
Night 45.5 ± 6.0 48.7 ± 5.3 27.9 ± 5.2 35.7 ± 6.0 18.5 _+ 6.9 39.8 _+ 9.5 
Volume aspirated (median, 9 6 10 5.5 6 10 
interquartile range) 4, 19 1, 15 3, 22.5 1, 20.5 0.5, 11.5 4, 32 
HA, hyaluronic acid; TA, triamcinolone hexacetonide. 
Summary  stat ist ics for the main outcome 
measures  are presented (Table III). Dur ing  the 6- 
month  follow-up per iod a stat ist ica l ly  s igni f icant 
di f ference in all parameters  in favor of the HA 
group developed in those pat ients  who remained  in 
the study (Figs 1 & 2). However, there  was a 
s igni f icant wi thdrawal  rate in both groups. This 
was main ly  because pat ients  developed symptoms 
for which they wished to resume thei r  NSAID 
medicat ion.  Analys is  of the data employ ing an 
intent ion  to treat,  last -measure  car r ied  forward 
method,  reduced the size of the di f ference between 
the two groups to a stat ist ical ly non-s igni f icant level; 
but the t rend remained  in favor of HA (Fig. 2). 
Compar i son  between the t reated and p lacebo 
knees is hampered  by the lack of t rue  randomiz-  
ation. No di f ference between the two knees  in terms 
of change in VAS score is(however, demonst ra ted  for 
e i ther  HA (Fig. 3) or TH (data not  shown). 
Analys is  of the wi thdrawals  demonst ra ted  no 
s igni f icant di f ferences between the groups e i ther  in 
the t iming of, or reason  for, withdrawal .  
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FIG. I. Pain at night for patients remaining in the study (mean ± S.E.). m: Triameinolone-treated group; 0:  hyaluronic 
acid-treated group. VAS, visual analog score. 
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FIG. 2. Pain on nominated activity for patients remaining in study (mean +_ S.E.). m: Triamcinolone-treated group; 
~: hyaluronic acid-treated group. VAS, visual analog score. 
Discuss ion  
These data are cons istent  with a s imi lar  
short - term benefit  f rom TH and HA but a longer 
course of act ion of HA. Nevertheless,  this resu l t  
must  be in terpreted  with caut ion  due to the 
substant ia l  wi thdrawal  rate dur ing the follow-up 
period. We were unable to show a s ignif icant benefit  
of active t reatment  over placebo. However since 
placebo therapy was not randomized,  in t rapat ient  
compar ison with the actively t reated knee is 
problematic  since it confuses t reatment  effect wi th  
the effect of pain sever i ty at study entry. 
Compar ison between the two p lacebo groups is 
legi t imate since a l locat ion was random. The f inding 
that  the p lacebo-treated knee of the HA group 
showed a s imi lar  response to the active knee is, 
therefore, interest ing. Several  exp lanat ions  might  
be offered. The response observed may be due to a 
placebo effect; certa in ly  f requent  contact  with 
hea l thcare  professionals may have a s ignif icant 
therapeut ic  effect [14]. S imi lar ly  the therapeut ic  
effect of f requent  ar throcentes is  is impossible 
to d iscount  due to the lack of a no- intervent ion 
group. However the dif ference in response between 
the two p lacebo groups, TH and HA, would argue 
against  hese explanat ions.  The s imi lar  response in 
both  knees of the same pat ient  might  be in terpreted  
• t~ 
as an lmiSrovement effect in a cont ra la tera l  jo int  v ia 
neurogenic  reflexes after local  t reatment  at one site, 
an unproven hypothesis.  Otherwise,  pain and 
stiffness at one site might  affect repor t ing  of 
symptoms at another  site, reduc ing the abi l i ty of the 
pat ient  o discern differences. Interest ingly,  s imi lar  
f indings have recent ly  been repor ted  by other  
workers explor ing the mechan ism of act ion of 
HA [15]. 
The s imi lar i ty  of eff icacy of HA and TH is 
encourag ing  since HA is, as far as is known, not 
subject  to any of the theoret ica l  r isks that  are 
assoc iated wi th  in t ra -ar t icu lar  steroids. Further-  
more  the observat ion that  HA may have a longer 
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Pain on nominated activity (mean _+ S.E.). i :  Hyaluronic acid-treated knee; 0: Placebo-treated knee. 
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durat ion  of act ion is impor tant  and may be 
an impor tant  addi t ion to the therapeut ic  a rmamen-  
ta r ium to osteoarthr i t is .  However  such a f inding 
needs conf i rmat ion s ince the number  and f requency 
of in ject ion (weekly for 5 weeks) may be an adverse 
factor  in pat ient  acceptab i l i ty  if only assoc iated 
with shor t - term benefit.  
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